Source: REUTERS, 10/26/17

German drugmaker Bayer on Thursday flagged it might reduce the size of its planned rights issue to fund the planned $66 billion takeover of Monsanto, citing proceeds from an antitrust-related asset sale to rival BASF “We will also use the net proceeds from the announced divestiture to BASF to refinance the Monsanto acquisition,” Chief Executive Werner Baumann said in prepared remarks published ahead of a conference call for journalists. 

For more of this story, click here.